Journal
JAMA PEDIATRICS
Volume 167, Issue 4, Pages 355-360Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jamapediatrics.2013.1045
Keywords
-
Categories
Funding
- Amylin
- Eli Lilly
- Community Health Collaborative grant from the University of Minnesota Clinical and Translational Science Institute
- National Center for Research Resources [1UL1RR033183]
- National Center for Advancing Translational Sciences of the National Institutes of Health [8UL1TR000114-02]
Ask authors/readers for more resources
Importance: Medical treatment options for pediatric obesity remain limited. Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and increasing satiety, but few studies have evaluated this therapy as a treatment for obesity. Objective: To evaluate the effects of exenatide on body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and cardiometabolic risk factors in adolescents with severe obesity. Design: Three-month, randomized, double-blind, placebo-controlled, multicenter clinical trial followed by a 3-month open-label extension. Setting: An academic medical center and an outpatient pediatric endocrinology clinic. Patients: A total of 26 adolescents (12-19 years of age) with severe obesity (BMI >= 1.2 times the 95th percentile or BMI >= 35). Intervention: All patients received lifestyle modification counseling and were equally randomized to exenatide or placebo injection, twice per day. Main Outcome Measures: The primary end point was the mean percent change in BMI measured at baseline and 3 months. Secondary end points included absolute change in BMI, body weight, body fat, blood pressure, hemoglobin A(1c), fasting glucose, fasting insulin, and lipids at 3 months. Results: Twenty-two patients completed the trial. Exenatide elicited a greater reduction in percent change in BMI compared with placebo (-2.70% [95% CI, -5.02% to -0.37%]; P = .03). Similar findings were observed for absolute change in BMI (-1.13 [95% CI, -2.03 to -0.24]; P = .02) and body weight (-3.26 kg [95% CI, -5.87 to -0.66 kg]; P = .02). Although not reaching the level of statistical significance, reduction in systolic blood pressure was observed with exenatide. During the open-label extension, BMI was further reduced in those initially randomized to exenatide (cumulative BMI reduction of 4%). Conclusions and Relevance: These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available